The Drug-Induced Respiratory Disease Website
A broad term often representing life-threatening scenarios including myocarditis, dysrhythmias, ventricular tachycardia, conduction abnormalities, heart failure, and/or valvular heart disease (PMID 29912044, 29980467)
Publications
Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.
Translational oncology 2022 Mar 03;19;101383 — 2022 Mar 03 — 101383
Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, Pariente A, Gobert A, Spano JP, Balko JM, Bonaca MP, Roden DM, Johnson DB, Moslehi JJ
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
The Lancet. Oncology 2018 12;19;1579-1589 — 2018 12 — 1579-1589
Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area.
The Canadian journal of cardiology 2018 08;34;1059-1068 — 2018 08 — 1059-1068
Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
Current oncology reports 2018 04 11;20;44 — 2018 04 11 — 44
Heinzerling L, Ott PA, Hodi FS, Husain AN, Tajmir-Riahi A, Tawbi H, Pauschinger M, Gajewski TF, Lipson EJ, Luke JJ
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Journal for immunotherapy of cancer 2016;4;50 — 2016 — 50